Vikram Malhi

595 total citations
23 papers, 427 citations indexed

About

Vikram Malhi is a scholar working on Molecular Biology, Oncology and Pharmacy. According to data from OpenAlex, Vikram Malhi has authored 23 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Pharmacy. Recurrent topics in Vikram Malhi's work include Hedgehog Signaling Pathway Studies (9 papers), Oral and gingival health research (6 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Vikram Malhi is often cited by papers focused on Hedgehog Signaling Pathway Studies (9 papers), Oral and gingival health research (6 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Vikram Malhi collaborates with scholars based in United States, France and Spain. Vikram Malhi's co-authors include Richard Graham, Yuan Chen, Jane R. Kenny, Jin Y. Jin, Sophie Mukadam, Bert L. Lum, Cornelis E. C. A. Hop, Jennifer A. Low, Dawn Colburn and Ilsung Chang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Medicinal Chemistry.

In The Last Decade

Vikram Malhi

23 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vikram Malhi United States 11 234 130 81 68 52 23 427
Kosalaram Goteti United States 13 134 0.6× 91 0.7× 60 0.7× 36 0.5× 41 0.8× 32 489
Su Sien Ong United States 12 187 0.8× 200 1.5× 201 2.5× 94 1.4× 43 0.8× 15 558
Tarundeep Kakkar United States 10 252 1.1× 94 0.7× 66 0.8× 20 0.3× 29 0.6× 18 538
Hans-Peter Gschwind Switzerland 10 181 0.8× 97 0.7× 46 0.6× 20 0.3× 52 1.0× 15 466
Lakshmi Vasist United States 11 221 0.9× 185 1.4× 55 0.7× 11 0.2× 48 0.9× 17 480
Florent Puisset France 13 106 0.5× 215 1.7× 100 1.2× 20 0.3× 113 2.2× 35 521
Gérard Sanderink France 11 243 1.0× 412 3.2× 142 1.8× 27 0.4× 102 2.0× 17 866
Kim Edmonds United Kingdom 9 222 0.9× 317 2.4× 21 0.3× 31 0.5× 84 1.6× 16 560
Larry House United States 12 330 1.4× 252 1.9× 112 1.4× 15 0.2× 112 2.2× 30 604
Chiyo K. Imamura Japan 14 212 0.9× 326 2.5× 255 3.1× 235 3.5× 113 2.2× 54 795

Countries citing papers authored by Vikram Malhi

Since Specialization
Citations

This map shows the geographic impact of Vikram Malhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikram Malhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikram Malhi more than expected).

Fields of papers citing papers by Vikram Malhi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikram Malhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikram Malhi. The network helps show where Vikram Malhi may publish in the future.

Co-authorship network of co-authors of Vikram Malhi

This figure shows the co-authorship network connecting the top 25 collaborators of Vikram Malhi. A scholar is included among the top collaborators of Vikram Malhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikram Malhi. Vikram Malhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Malhi, Vikram, et al.. (2024). UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer Chemotherapy and Pharmacology. 94(1). 117–122. 1 indexed citations
2.
Kshirsagar, Smita, Ya‐Chi Chen, Jiajie Yu, et al.. (2024). Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects. Drug Metabolism and Disposition. 52(8). 847–857. 2 indexed citations
3.
Malhi, Vikram, Mary Gates, Lichuan Liu, et al.. (2023). Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer. Cancer Research Communications. 3(12). 2551–2559. 2 indexed citations
4.
Yoshida, Kenta, Vikram Malhi, Chunze Li, et al.. (2023). Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes. Clinical and Translational Science. 16(5). 823–834. 2 indexed citations
5.
Takahashi, Ryan, Vikram Malhi, Bianca M. Liederer, et al.. (2023). The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor. Drug Metabolism and Disposition. 51(10). 1332–1341. 4 indexed citations
6.
Schjesvold, Fredrik, Bruno Paiva, Vincent Ribrag, et al.. (2022). Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(1). e59–e70. 10 indexed citations
7.
Malhi, Vikram, Nageshwar Budha, Rucha Sane, et al.. (2021). Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Cancer Chemotherapy and Pharmacology. 88(6). 921–930. 4 indexed citations
8.
9.
Sane, Rucha, Eunpi Cho, Bianca M. Liederer, et al.. (2021). Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics. 378(2). 87–95. 16 indexed citations
10.
Chen, Ya‐Chi, Jiajie Yu, Ciara Metcalfe, et al.. (2021). Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opinion on Investigational Drugs. 31(6). 515–529. 48 indexed citations
11.
12.
Graham, Richard, Cornelis E. C. A. Hop, Marie T. Borin, et al.. (2012). Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. British Journal of Clinical Pharmacology. 74(5). 788–796. 49 indexed citations
13.
LoRusso, Patricia, Sarina A. Piha‐Paul, Monica Mita, et al.. (2012). Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential. Cancer Chemotherapy and Pharmacology. 71(1). 193–202. 17 indexed citations
14.
Chen, Yuan, Jin Y. Jin, Sophie Mukadam, Vikram Malhi, & Jane R. Kenny. (2012). Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharmaceutics & Drug Disposition. 33(2). 85–98. 81 indexed citations
15.
16.
Graham, Richard, Bert L. Lum, Glenn Morrison, et al.. (2011). A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry. Drug Metabolism and Disposition. 39(8). 1460–1467. 48 indexed citations
17.
LoRusso, Patricia, Sarina A. Piha‐Paul, A. Dimitrios Colevas, et al.. (2011). Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B188–B188. 2 indexed citations
18.
Giannetti, Anthony M., Harvey Wong, Gerrit J.P. Dijkgraaf, et al.. (2011). Identification, Characterization, and Implications of Species-Dependent Plasma Protein Binding for the Oral Hedgehog Pathway Inhibitor Vismodegib (GDC-0449). Journal of Medicinal Chemistry. 54(8). 2592–2601. 60 indexed citations
19.
Graham, Richard, Ilsung Chang, Karin Jorga, et al.. (2010). Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects.. Journal of Clinical Oncology. 28(15_suppl). e13009–e13009. 1 indexed citations
20.
Lum, B., Ilsung Chang, Karin Jorga, et al.. (2010). A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential.. Journal of Clinical Oncology. 28(15_suppl). 2558–2558. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kosalaram Goteti Breakdown of academic impact, for papers by Su Sien Ong Breakdown of academic impact, for papers by Tarundeep Kakkar Breakdown of academic impact, for papers by Hans-Peter Gschwind Breakdown of academic impact, for papers by Lakshmi Vasist Breakdown of academic impact, for papers by Florent Puisset Breakdown of academic impact, for papers by Gérard Sanderink Breakdown of academic impact, for papers by Kim Edmonds Breakdown of academic impact, for papers by Larry House Breakdown of academic impact, for papers by Chiyo K. Imamura
Rankless by CCL
2026